Once sidelined, Eli Lilly’s COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreementnews2021-11-02T13:43:52+00:00November 2nd, 2021|Fierce Pharma|
Lonza snaps up Codiak’s exosome manufacturing site for $65M of ‘in kind’ servicesnews2021-11-02T13:25:59+00:00November 2nd, 2021|Fierce Pharma|
In the CDMO industry’s expansion blitz, Samsung Biologics goes full speed ahead with ‘Super Plant,’ plans to grow global footprintnews2021-11-02T12:08:29+00:00November 2nd, 2021|Fierce Pharma|
GenScript embraces automation at its first cell, gene therapy manufacturing US sitenews2021-11-02T11:56:11+00:00November 2nd, 2021|Fierce Pharma|
Meissa posts early clinical data on nasal COVID-19 vaccine, providing support for role in breaking transmission chainsnews2021-11-02T09:20:28+00:00November 2nd, 2021|Fierce Pharma|
Stallergenes, seeking an edge in a competitive space, taps Aptar for connected drug delivery projectnews2021-11-01T16:23:56+00:00November 1st, 2021|Fierce Pharma|
AbbVie’s Parkinson’s pump hits goal in phase 3, setting stage for approval filingsnews2021-11-01T16:20:47+00:00November 1st, 2021|Fierce Pharma|
AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covisnews2021-11-01T15:19:57+00:00November 1st, 2021|Fierce Pharma|
Jaguar to pump $125M into North Carolina gene therapy manufacturing facilitynews2021-11-01T14:20:28+00:00November 1st, 2021|Fierce Pharma|
Amid a push to resolve opioid and talc claims, Johnson & Johnson settles Risperdal litigation for $800Mnews2021-11-01T14:08:55+00:00November 1st, 2021|Fierce Pharma|
